文献速递甲状腺疾病垂体与肾上腺疾病

凡德他尼长期控制伴体细胞RET突变的甲状腺髓样癌一例中的皮质醇增多症

Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
PubMed 文献 · Thyroid · 2017-03-13

报告一例58岁男性甲状腺髓样癌相关异位库欣综合征患者,对多种抗皮质醇药物联合治疗抵抗,起始凡德他尼后皮质醇增多症迅速逆转而肿瘤大小无变化。两次短暂中断凡德他尼期间血浆皮质醇和降钙素升高,重新用药后迅速下降。起始凡德他尼3年8个月后无皮质醇增多症复发迹象。

要点

  • 甲状腺髓样癌相关库欣综合征患者对肾上腺阻断药物抵抗时,凡德他尼可使皮质醇增多症迅速逆转。
  • 中断凡德他尼后血浆皮质醇和降钙素升高,重新用药后迅速下降,提示其抗分泌作用。
  • 凡德他尼治疗期间去氨加压素刺激后ACTH反应减弱,支持酪氨酸激酶抑制剂抗分泌作用。

核心结论

  • 起始凡德他尼3年8个月后无皮质醇增多症复发迹象,本病例说明凡德他尼在维持甲状腺髓样癌相关库欣综合征皮质醇增多症控制方面具有长期有效性。

研究设计与样本

  • 病例报告:一例58岁男性甲状腺髓样癌相关库欣综合征患者,对多种抗皮质醇药物联合治疗抵抗。

主要发现

  • 起始凡德他尼后皮质醇增多症迅速逆转,肿瘤大小无任何变化。
  • 凡德他尼两次短暂中断(一次因副作用中断45天,另一次为安排手术减瘤中断10天),每次中断后血浆皮质醇和降钙素水平升高,重新引入凡德他尼后迅速降低。
  • 凡德他尼治疗前去氨加压素刺激后ACTH明显升高,而凡德他尼治疗全程去氨加压素刺激后ACTH反应减弱。
  • 起始凡德他尼一年后行左甲状腺叶切除和改良颈淋巴结清扫以减小肿瘤体积。
  • 淋巴结转移灶中检出激活型M918T RET(c.2753T>C)体细胞突变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medullary thyroid carcinomas (MTCs) complicated by ectopic Cushing's syndrome (CS) have a poor prognosis, partially due to the difficulty in controlling hypercortisolism by adrenal blocking drugs. Recent reports (including the initial follow-up of this patient) have suggested that tyrosine kinase inhibitors (TKIs) may be a therapeutic option due to an anti-secretory action on ACTH. However, there is a lack of long-term follow-up studies. PATIENT FINDINGS: The case is reported of a 58-year-old man with MTC-related CS resistant to a combination of several anti-cortisolic drugs. Vandetanib, an oral multi-TKI that targets RET in particular, was initiated, and a rapid reversal of the hypercortisolism was observed without any change in tumor size. Vandetanib was briefly interrupted twice, once for 45 days because of side effects and a second time for 10 days to schedule surgical debulking. Each time, plasma cortisol and calcitonin levels increased after TKI withdrawal and were rapidly lowered by vandetanib reintroduction. As described in other cases of CS caused by MTC, a marked ACTH increase after desmopressin stimulation was observed before vandetanib therapy. In contrast, a blunted ACTH response to desmopressin was documented throughout the course of vandetanib treatment. This modulation of the tumoral ACTH production is a strong argument in favor of a TKI anti-secretory action. A left thyroid lobectomy and a modified neck dissection were performed one year after the initiation of vandetanib in order to reduce the tumor mass. An activating M918T RET (c.2753T>C) somatic mutation was identified in a lymph node metastasis. CONCLUSION: Three years and eight months after vandetanib initiation, there was no sign of recurrence of hypercortisolism. This case illustrates the long-term effectiveness of vandetanib in maintaining the control of hypercortisolism in MTC-related CS.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Paepegaey AC, Cochand-Priollet B, Louiset E, et al. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation. Thyroid. 2017. PMID: 28068878. doi:10.1089/thy.2016.0334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。